Abstract 279: Eligibility and Cost Estimates for Anti-inflammatory Therapy for Atherosclerotic Disease: Implications of the CANTOS Trial for the US Adult Population [Session Title: Poster Session PM]

Conclusion: Nearly 1 in 3 or 2.1 million US adults with a prior MI are potential treatment candidates. Assuming current canakinumab prices would incur an annual financial burden of up to 124 billion dollars in the United States. Further work is needed to define the population that achieves favorable value with treatment.

Source: Circulation: Cardiovascular Quality and Outcomes - April 5, 2018 Category: Cardiology Authors: Khera, R., Saxena, A., Hong, J., Arrieta, A., Ross, J. S., Krumholz, H. M., Nasir, K. Tags: Session Title: Poster Session PM Source Type: research